Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712450 | 1.00 | CYP1A2 (0.47) | CYP1A2KMT2AMEN1CYP2D6HIF1A | |
| SCHEMBL1712531 | 1.00 | CYP1A2 (0.47) | CYP1A2KMT2AMEN1CYP2D6HIF1A | |
| Hydrochloric Acid SCHEMBL8064648 | 0.98 | CYP1A2 (0.46) | CYP1A2KMT2AMEN1CYP2D6HIF1A | |
| SCHEMBL10885482 | 0.85 | MAPT (0.50) | CYP1A2KMT2ACYP2D6HIF1ASMN1; SMN2 | |
| SCHEMBL11826573 | 0.83 | CYP1A2 (0.44) | CYP1A2KMT2AMEN1CYP2D6HIF1A | |
| SCHEMBL1081535 | 0.83 | CYP1A2 (0.47) | CYP1A2KMT2AMEN1CYP2D6HIF1A | |
| SCHEMBL2089245 | 0.81 | CYP1A2 (0.70) | CYP1A2KMT2AMEN1CYP2D6HIF1A | |
| SCHEMBL305912 | 0.81 | CYP1A2 (0.70) | CYP1A2KMT2AMEN1CYP2D6HIF1A | |
| SCHEMBL7617984 | 0.81 | CYP1A2 (0.48) | CYP1A2KMT2AMEN1CYP2D6HIF1A | |
| SCHEMBL8783850 | 0.81 | HIF1A (0.53) | CYP1A2KMT2AMEN1CYP2D6HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344460-B1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8383608-B2 | Imidazolidine compounds as androgen receptor modulators | DART THERAPEUTICS LLC | 2013-02-26 | — | — | US | disclosed |
| US-20120178718-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-2344460-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Galapagos N.V. (BE) | 2011-07-20 | — | — | EP | disclosed |
| US-7968581-B2 | Imidazolidine compounds as androgen receptor modulators | GALAPAGOS NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010029119-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | GALAPAGOS NV (BE) | 2010-03-18 | — | — | WO | disclosed |
| US-5959141-A | 1-amino-2-hydroxycycloalkanecarboxylic acid derivatives | SUNTORY LIMITED (JP) | 1999-09-28 | — | — | US | disclosed |
| EP-0844992-A1 | PROCESS FOR PRODUCING $g(b)-AMINO-$g(a)-HYDROXYCARBOXYLIC ACIDS AND DERIVATIVES THEREOF | Degussa Aktiengesellschaft (DE) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997002236-A1 | PROCESS FOR PRODUCING β-AMINO-α-HYDROXYCARBOXYLIC ACIDS AND DERIVATIVES THEREOF | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178718-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, GNRHR | CYP1A2 1325/4885KMT2A 2306/4885MEN1 1659/4885 |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, GNRHR | CYP1A2 1056/4885KMT2A 2038/4885MEN1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.